Table 7.
Echocardiographic (2DE/3DE) outcome measures
| Baseline | 12 weeks | |||
|---|---|---|---|---|
| Ranolazine (N = 4) | Placebo (N = 6) | Ranolazine (N = 4) | Placebo (N = 6) | |
| LV EF, % | 66.3 (8.8) | 66.0 (8.0) | 67.3 (6.0) | 64.0 (4.0) |
| LV EDD, cm | 4.2 (0.9) | 4.5 (0.8) | 4.3 (0.2) | 4.4 (0.3) |
| IVSd, cm | 0.9 (0.1) | 1.1 (0.2) | 1.0 (0.1) | 1.0 (0.1) |
| PWd, cm | 0.9 (0.1) | 1.0 (0.2) | 0.9 (0.2) | 1.0 (0.1) |
| RV base, cm | 4.7 (1.1) | 4.4 (1.1) | 4.7 (0.8) | 4.5 (0.6) |
| RV mid, cm | 2.8 (0.5) | 3.1 (1.0) | 3.2 (0.6) | 3.5 (0.7) |
| RV length, cm | 8.0 (1.2) | 7.7 (2.0) | 7.8 (1.9) | 8.1 (2.2) |
| RA/IVC pressure, mmHg | 15.0 (10.0) | 7.5 (7.5) | 7.5 (0) | 7.5 (0) |
| TR max gradient, mmHg | 58.7 (16.4) | 60.0 (33.0) | 61.0 (20.0) | 61.1 (20.0) |
| TAPSE, cm | 1.9 (0.7) | 1.7 (0.6) | 1.9 (0.8) | 2.3 (0.5) |
| S′, cm/s | 11.6 (1.9) | 11.5 (2.4) | 12.3 (3.3) | 12.7 (2.8) |
| RV ED area, cm2 | 23.5 (6.5) | 29.9 (7.2) | 26.1 (4.5) | 26.7 (7.9) |
| FAC, % | 28.1 (4) | 27.6 (16.5) | 31.1 (8.8) | 27.6 (6.9) |
| RVFWLS, % | −16.7 (3.3) | −23.7 (7.9) | −14.4 (8.9) | −21.9 (8.2) |
| 3DE EF, % | 30.7 (4.3) | 17.9 (12.2) | 32.0 (0) | 23.4 (13.9) |
Note
Data are median (interquartile range). ED: end-diastolic; EDD: end-diastolic dimension; EF: ejection fraction; FAC: fractional area change; IVC: inferior vena cava; IVSd: interventricular septum dimension; LV: left ventricle; PWd: posterior wall dimension, RA: right atrium; RV: right ventricle; RVFWLS: right ventricular free-wall longitudinal strain; S′: maximal systolic excursion velocity, from pulsed tissue Doppler; TAPSE: tricuspid annular plane systolic excursion; TR max: tricuspid regurgitation maximum; 2DE: 2-dimensional echocardiography, 3DE: 3-dimensional echocardiography.